RxDoctor Payments Data

Hannah Do, MD

Gastroenterology · Doylestown, PANPI 1770808990

Payments from drug & device makers

$8,549in general payments, 2019–2025

Across 482 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$835
  • Johnson & Johnson$653
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$614
  • Pfizer$368
  • Bristol Myers Squibb$324
  • plus $4K from 38 others

What the payments were for

  • Consulting fees$130%
  • Food & beverage$8,46799%
  • Education$691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,549 in reported general payments places this provider in the 70th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$422,517
Medicare patients
565
Services billed
13,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi On-BodyRisankizumab-Rzaa16$333,902
LinzessLinaclotide41$53,621
Mesalamine24$15,399
SutabSod Sulf/Pot Chloride/Mag Sulf71$11,314
Dexlansoprazole DrDexlansoprazole15$7,138
Omeprazole571$6,572
Pantoprazole Sodium323$4,815
Famotidine295$3,428
Colestipol Hcl21$3,341
Esomeprazole Magnesium62$2,562
Balsalazide Disodium17$2,440
Lubiprostone12$2,186
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag14$1,710
Lansoprazole45$1,453
Sucralfate22$798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,911$53,62141 claims
Braintree Laboratories, Inc.Sutab, Suflave$237$13,02485 claims
SandozLansoprazole$15$1,45345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →